Home > Back to Publisher > Report Information

Urinary Tract Cancer - Pipeline Review, H1 2012

Global Markets Direct
January 23, 2012
374 Pages - SKU: GMD6775946

Abstract Table of Contents Search inside this report Related Reports

Urinary Tract Cancer - Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Urinary Tract Cancer - Pipeline Review, H1 2012', provides an overview of the Urinary Tract Cancer therapeutic pipeline. This report provides information on the therapeutic development for Urinary Tract Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Urinary Tract Cancer. 'Urinary Tract Cancer - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

A snapshot of the global therapeutic scenario for Urinary Tract Cancer.
A review of the Urinary Tract Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
Coverage of products based on various stages of development ranging from discovery till registration stages.
A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
Coverage of the Urinary Tract Cancer pipeline on the basis of route of administration and molecule type.
Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
Key discontinued pipeline projects.
Latest news and deals relating to the products.

Reasons to buy

Identify and understand important and diverse types of therapeutics under development for Urinary Tract Cancer.
Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
Devise corrective measures for pipeline projects by understanding Urinary Tract Cancer pipeline depth and focus of Urinary Tract Cancer therapeutics.
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Introduction: Global Markets Direct Report Coverage; Urinary Tract Cancer Overview; Therapeutics Development; An Overview of Pipeline Products for Urinary Tract Cancer; Urinary Tract Cancer Therapeutics under Development by Companies; Urinary Tract Cancer Therapeutics under Investigation by Universities/Institutes; Late Stage Products; Comparative Analysis; Mid Clinical Stage Products; Comparative Analysis; Early Clinical Stage Products; Comparative Analysis; Discovery and Pre-Clinical Stage Products; Comparative Analysis; Urinary Tract Cancer Therapeutics - Products under Development by Companies; Urinary Tract Cancer Therapeutics - Products under Investigation by Universities/Institutes; Companies Involved in Urinary Tract Cancer Therapeutics Development; Bristol-Myers Squibb Company; Genzyme Corporation; Boehringer Ingelheim GmbH; F. Hoffmann-La Roche Ltd.; Kyowa Hakko Kirin Co., Ltd.; Shionogi & Co., Ltd.; Amgen Inc.; Medical Enzymes AG; IkerChem S.L.; Immunovative Therapies, Ltd.; Urinary Tract Cancer - Therapeutics Assessment; Assessment by Monotherapy Products; Assessment by Combination Products; Assessment by Route of Administration; Assessment by Molecule Type; Drug Profiles; Nexavar - Drug Profile; Axitinib - Drug Profile; Axitinib - Drug Profile; Sutent - Drug Profile; Sotatercept - Drug Profile; ANYARA - Drug Profile; IMA901 - Drug Profile; TroVax - Drug Profile; NuLeusin - Drug Profile; Urocidin - Drug Profile; Eoquin - Drug Profile; Tivozanib - Drug Profile; Rencarex - Drug Profile; Dovitinib - Drug Profile; Selenium + Vitamin E - Drug Profile; Celecoxib - Drug Profile; Methotrexate + Cisplatin - Drug Profile; Aldesleukin for Kidney Cancer - Drug Profile; Aldesleukin + Recombinant interferon alfa + Fluorouracil - Drug Profile; Bevacizumab + Torisel - Drug Profile; Gemcitabine + Cisplatin + Bevacizumab - Drug Profile; Interferon Alfa-2B + Bevacizumab - Drug Profile; Interferon Alfa-2B - Drug Profile; BAY43-9006 - Drug Profile; Sunitinib - Drug Profile; Uracil-Tegafur - Drug Profile; Gemcitabine - Drug Profile; Javlor - Drug Profile; Fenretinide - Drug Profile; Methotrexate + Vinblastine + Doxorubicin + Cisplatin - Drug Profile; Cisplatin + Adriamycin + Methotrexate + Vinblastine - Drug Profile; Dactinomycin + Doxorubicin + Vincristine - Drug Profile; Sorafenib Tosylate - Drug Profile; Larotaxel + Cisplatin - Drug Profile; Recombinant Interferon Alfa + Isotretinoin - Drug Profile; Interferon Alfa + CCI-779 - Drug Profile; BCG Vaccine + Iressa - Drug Profile; Fluorouracil + Mitomycin C + Radiation Therapy - Drug Profile; Interleukin-2 - Drug Profile; Dactinomycin + Filgrastim + Cylophosphamide + Doxorubicin hydrochloride + Etoposide + Vincristine sulfate + Radiation therapy - Drug Profile; RAD001 - Drug Profile; TroVax + IL-2 - Drug Profile; Interferon-Alpha + Interleukin-2 + 5-Fluorouracil - Drug Profile; Filgrastim + Doxorubicin + Ifosfamide - Drug Profile; Mitomycin C - Drug Profile; Interferon-Alpha - Drug Profile; Mitomycin + Hyperthermia Therapy - Drug Profile; Cisplatin + Cyclophosphamide + Adriamycin - Drug Profile; Votrient - Drug Profile; Everolimus + Bevacizumab - Drug Profile; ANYARA + Interferon Alpha - Drug Profile; Sunitinib - Drug Profile; Interferon-alpha - Drug Profile; MVAC Therapy - Drug Profile; BCG Therapy - Drug Profile; Interleukin 2 + Interferon-alpha2 - Drug Profile; Dactinomycine + Doxorubicin + Vincristine + Radiation Therapy - Drug Profile; Cisplatin + Radiation Therapy - Drug Profile; Mitomycin C - Drug Profile; Sorafenib - Drug Profile; Sorafenib + Sunitinib - Drug Profile; bevacizumab + recombinant interferon alfa - Drug Profile; Carboplatin + Methotrexate + Vinblastine - Drug Profile; Cisplatin + Doxorubicin + Gemcitabine + Methotrexate + Vinblastine + Filgrastim - Drug Profile; aldesleukin + recombinant interferon alfa + fluorouracil - Drug Profile; Dactinomycin + Carboplatin + Cyclophosphamide + Doxorubicin Hydrochloride + Etoposide + Vincristine Sulfate - Drug Profile; Doxorubicin hydrochloride - Drug Profile; Gemcitabine + Cisplatin - Drug Profile; Sunitinib - Drug Profile; Recombinant Gamma Interferon - Drug Profile; Methotrexate - Drug Profile; Thiotepa - Drug Profile; Bacillus Calmette-Guerin Vaccine - Drug Profile; Cisplatin + Radiation Therapy - Drug Profile; Pirarubicin - Drug Profile; Sunitinib - Drug Profile; Bevacizumab + Interferon Alfa-2a - Drug Profile; Urinary Tract Cancer Therapeutics - Drug Profile Updates; Urinary Tract Cancer Therapeutics - Discontinued Products; Urinary Tract Cancer Therapeutics - Dormant Products; Urinary Tract Cancer - Product Development Milestones; Featured News & Press Releases
Appendix: Methodology; Expert Panel Validation; Contact Us; Disclaimer
List of Tables: Number of Products Under Development for Urinary Tract Cancer, H1 2012; Products under Development for Urinary Tract Cancer - Comparative Analysis, H1 2012; Number of Products under Development by Companies, H1 2012; Number of Products under Investigation by Universities/Institutes, H1 2012; Comparative Analysis by Late Stage Development, H1 2012; Comparative Analysis by Mid Clinical Stage Development, H1 2012; Comparative Analysis by Early Clinical Stage Development, H1 2012; Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012; Products under Development by Companies, H1 2012; Products under Investigation by Universities/Institutes, H1 2012; Bristol-Myers Squibb Company, H1 2012; Genzyme Corporation, H1 2012; Boehringer Ingelheim GmbH, H1 2012; F. Hoffmann-La Roche Ltd., H1 2012; Kyowa Hakko Kirin Co., Ltd., H1 2012; Shionogi & Co., Ltd., H1 2012; Amgen Inc., H1 2012; Sanofi-Aventis, H1 2012; AstraZeneca PLC, H1 2012; Eli Lilly and Company, H1 2012; GlaxoSmithKline plc, H1 2012; Seattle Genetics, Inc., H1 2012; Bioniche Life Sciences, Inc., H1 2012; Genentech, Inc., H1 2012; Merck & Co., Inc., H1 2012; Emergent BioSolutions Inc., H1 2012; Oxford BioMedica plc, H1 2012; Light Sciences Oncology, Inc., H1 2012; Novartis AG, H1 2012; ImClone Systems Incorporated, H1 2012; Astellas Pharma Inc., H1 2012; Eisai Co., Ltd., H1 2012; Genta Incorporated, H1 2012; MDRNA, Inc., H1 2012; Ono Pharmaceutical Co., Ltd., H1 2012; OSI Pharmaceuticals, Inc., H1 2012; Pfizer Inc., H1 2012; Taiho Pharmaceutical Co., Ltd., H1 2012; Exelixis, Inc., H1 2012; Alfacell Corporation, H1 2012; Celgene Corporation, H1 2012; Bayer AG, H1 2012; MannKind Corporation, H1 2012; Halozyme Therapeutics, H1 2012; 3SBio Inc., H1 2012; EntreMed, Inc., H1 2012; Celldex Therapeutics, Inc., H1 2012; Active Biotech AB, H1 2012; AEterna Zentaris Inc., H1 2012; AIDA Pharmaceuticals, Inc., H1 2012; Lorus Therapeutics Inc, H1 2012; Bionomics Limited, H1 2012; Northwest Biotherapeutics, Inc., H1 2012; Cleveland BioLabs, Inc., H1 2012; Oncolytics Biotech Inc., H1 2012; Patrys Limited, H1 2012; Keryx Biopharmaceuticals, Inc., H1 2012; ARQULE, INC, H1 2012; Allos Therapeutics, Inc, H1 2012; Flamel Technologies S.A., H1 2012; TopoTarget A/S, H1 2012; Oncogenex Pharmaceuticals, Inc., H1 2012; Dendreon Corporation, H1 2012; Sanochemia Pharmazeutika AG, H1 2012; Green Cross Corporation, H1 2012; MOLOGEN AG, H1 2012; OncoTherapy Science, Inc., H1 2012; Threshold Pharmaceuticals, Inc., H1 2012; Innate Pharma SA, H1 2012; Protox Therapeutics Inc., H1 2012; Rexahn Pharmaceuticals, Inc., H1 2012; PCI Biotech Holding ASA, H1 2012; Spectrum Pharmaceuticals, Inc., H1 2012; Debiopharm Group, H1 2012; Antisense Pharma GmbH, H1 2012; Wilex AG, H1 2012; Philogen S.p.A., H1 2012; Acceleron Pharma, Inc., H1 2012; Med Discovery SA, H1 2012; Cadila Pharmaceuticals Ltd., H1 2012; ERYtech Pharma, H1 2012; immatics biotechnologies GmbH, H1 2012; Curacyte AG, H1 2012; Argos Therapeutics, Inc., H1 2012; Cytheris SA, H1 2012; Altor BioScience Corporation, H1 2012; AgrenVec, S.L., H1 2012; Alethia Biotherapeutics Inc., H1 2012; Telormedix SA, H1 2012; Gene Signal International SA., H1 2012; MacroGenics, Inc., H1 2012; Pivotal BioSciences, Inc., H1 2012; Neotropix, Inc., H1 2012; Jennerex Biotherapeutics, Inc., H1 2012; Stemline Therapeutics, Inc., H1 2012; BioCancell Therapeutics, Inc., H1 2012; Endocyte, Inc., H1 2012; Polyphenon Pharma, H1 2012; Advenchen Laboratories, LLC, H1 2012; AndroScience Corporation, H1 2012; Immutep S.A., H1 2012; Syndax Pharmaceuticals, Inc., H1 2012; Esperance Pharmaceuticals, Inc., H1 2012; Welichem Biotech Inc., H1 2012; PharmaMar, S.A., H1 2012; Tigris Pharmaceuticals, Inc., H1 2012; Viventia Biotechnologies Inc., H1 2012; AVEO Pharmaceuticals, Inc., H1 2012; TRACON Pharmaceuticals, Inc., H1 2012; KAHR medical Ltd., H1 2012; Advanced Cancer Therapeutics, H1 2012; Targa Therapeutics Corp., H1 2012; Cytavis Biopharma GmbH, H1 2012; Medical Enzymes AG, H1 2012; IkerChem S.L., H1 2012; Immunovative Therapies, Ltd., H1 2012; Assessment by Monotherapy Products, H1 2012; Assessment by Combination Products, H1 2012; Assessment by Stage and Route of Administration, H1 2012; Assessment by Molecule Type, H1 2012; Urinary Tract Cancer Therapeutics - Drug Profile Updates; Urinary Tract Cancer Therapeutics - Discontinued Products; Urinary Tract Cancer Therapeutics - Dormant Products
List of Figures: Number of Products under Development for Urinary Tract Cancer, H1 2012; Products under Development for Urinary Tract Cancer - Comparative Analysis, H1 2012; Products under Development by Companies, H1 2012; Products under Investigation by Universities/Institutes, H1 2012; Late Stage Products, H1 2012; Mid Clinical Stage Products, H1 2012; Early Clinical Stage Products, H1 2012; Discovery and Pre-Clinical Stage Products, H1 2012; Assessment by Monotherapy Products, H1 2012; Assessment by Combination Products, H1 2012; Assessment by Route of Administration, H1 2012; Assessment by Stage and Route of Administration, H1 2012; Assessment by Molecule Type, H1 2012; Assessment by Stage and Molecule Type, H1 2012

Urinary Tract Cancer - Pipeline Review, H1 2012

Share this report

Other tasks

Research Assistance

Related Markets

Oncology/Hematology Reports

Free Alert Me service